Research Analysts Set Expectations for STERIS Q3 Earnings

STERIS plc (NYSE:STE) – Analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for shares of STERIS in a research report issued on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.31 per share for the quarter, up from their prior estimate of $2.30. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s FY2025 earnings at $9.08 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.54 EPS, Q4 2026 earnings at $2.81 EPS, FY2026 earnings at $9.99 EPS, Q1 2027 earnings at $2.48 EPS, Q2 2027 earnings at $2.59 EPS, Q3 2027 earnings at $2.63 EPS and FY2027 earnings at $10.35 EPS.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.03 earnings per share.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Finally, Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $262.50.

STERIS Stock Performance

NYSE STE opened at $218.54 on Thursday. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $21.57 billion, a PE ratio of 49.89 and a beta of 0.84. The business’s 50-day moving average price is $211.68 and its 200 day moving average price is $224.74. STERIS has a twelve month low of $197.82 and a twelve month high of $248.24.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Activity at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in STERIS by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,303,625 shares of the medical equipment provider’s stock valued at $556,786,000 after purchasing an additional 17,007 shares during the period. Principal Financial Group Inc. raised its position in STERIS by 9.5% during the third quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider’s stock valued at $270,230,000 after buying an additional 96,336 shares during the period. Franklin Resources Inc. lifted its stake in STERIS by 171.2% in the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after acquiring an additional 529,308 shares in the last quarter. Raymond James & Associates boosted its position in STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider’s stock worth $194,309,000 after acquiring an additional 12,005 shares during the period. Finally, Select Equity Group L.P. grew its stake in STERIS by 2.3% during the 2nd quarter. Select Equity Group L.P. now owns 732,848 shares of the medical equipment provider’s stock valued at $160,889,000 after acquiring an additional 16,492 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.